Skip to main content
Clinical Trials/NCT04126005
NCT04126005
Completed
Not Applicable

A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease

Aspa Therapeutics4 sites in 2 countries67 target enrollmentOctober 10, 2019
ConditionsCanavan Disease

Overview

Phase
Not Applicable
Intervention
Cohort 4 (Age > 5 Years)
Conditions
Canavan Disease
Sponsor
Aspa Therapeutics
Enrollment
67
Locations
4
Primary Endpoint
To characterize the natural history of Canavan disease
Status
Completed
Last Updated
15 days ago

Overview

Brief Summary

This study uses medical records that allow retrospective data extraction of critical milestone and motor function data. In addition, prospective assessments collect data relevant to the natural history of Canavan disease in children.

Detailed Description

The CANinform natural history study is the first multinational effort to rigorously gather both retrospective and prospective data from this patient population. Data collection includes extraction of retrospective data from medical records of living and deceased patients, and collection of prospective, longitudinal data from living patients and their parent(s)/caregiver(s). Motor function assessments are performed remotely in the home via video or in the clinic by qualified study team members. Families will be invited to attend clinic visits and/or will be followed remotely by the clinical site for approximately 3 years.

Registry
clinicaltrials.gov
Start Date
October 10, 2019
End Date
August 31, 2025
Last Updated
15 days ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Aspa Therapeutics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Meet age criteria of a specific cohort.
  • Confirmed clinical and biochemical diagnosis of Canavan disease.
  • Available medical records since birth that permit documentation of disease characteristics and developmental milestones.
  • Parent and/or legal guardian is able to read, understand, and sign the informed consent.

Exclusion Criteria

  • 1\. Patient does not meet the Inclusion Criteria.

Arms & Interventions

Cohort 4 (Age > 5 Years)

* Motor function assessments (remote or in-clinic) 12 months * Clinic assessments every 12 months

Cohort 5 (Deceased)

• The patient's medical history records will be reviewed. In addition, a parent interview will be performed.

Cohort 2 (Age ≥ 18 Months - 3 Years)

* Motor function assessments (remote or in-clinic) every 4 months * Clinic assessments every 6 months

Cohort 1 (Age < 18 Months)

* Motor function assessments (remote or in-clinic) every 2 months * Clinic assessments every 6 months

Cohort 3 (Age > 3 - 5 Years)

* Motor function assessments (remote or in-clinic) every 6 months * Clinic assessments every 6 months

Outcomes

Primary Outcomes

To characterize the natural history of Canavan disease

Time Frame: approximately 3 years

To enhance the understanding of the natural history of Canavan disease through retrospective data collection from patient medical records and prospective data collection from living patients, including: phenotypic characteristics and variability, genotype characteristics and variability, and disease progression and natural history.

Study Sites (4)

Loading locations...

Similar Trials